We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
-8.87%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.94B
AUM Growth
-$1.55B
(-34%)
Cap. Flow
-$1.01B
Cap. Flow
% of AUM
-34.35%
Top 10 Holdings %
Top 10 Hldgs %
43.7%
Holding
135
New
15
Increased
7
Reduced
68
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Monte Rosa Therapeutics
GLUE
|
+$65.1M |
| 2 |
Biomea Fusion
BMEA
|
+$56M |
| 3 |
JBIO
Jade Biosciences
JBIO
|
+$46.4M |
| 4 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
+$46M |
| 5 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$42.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
C4 Therapeutics
CCCC
|
+$76.5M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$52.4M |
| 3 |
Novavax
NVAX
|
+$45.3M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$43.6M |
| 5 |
Omeros
OMER
|
+$35.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.38% |
| 2 | Financials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $237M | 8.05% |
3,037,042
+287,042
| +10% | +$21.2M |
|
2
PUT
iShares Russell 2000 ETF
IWM
$79.8B
| $229M | 7.79% |
1,000,000
-1,000,000
| -50% | -$225M |
|
3
Atea Pharmaceuticals
AVIR
$376M
| $138M | 4.68% |
6,411,355
| – | – |
|
|
FMTX
4
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $118M | 3.99% |
4,721,589
+1,589
| +0% | +$42.7K |
|
5
BridgeBio Pharma
BBIO
$15.7B
| $115M | 3.9% |
1,880,980
-287,929
| -13% | -$16.4M |
|
6
Design Therapeutics
DSGN
$761M
| $106M | 3.6% |
5,414,850
+300,000
| +6% | +$7.57M |
|
7
Revolution Medicines
RVMD
$39.9B
| $106M | 3.6% |
3,338,166
+813,166
| +32% | +$28.4M |
|
8
Olema Pharmaceuticals
OLMA
$1B
| $86M | 2.92% |
3,073,485
-122,059
| -4% | -$3.47M |
|
9
BioAtla
BCAB
$5.46M
| $82.7M | 2.81% |
39,034
-4,807
| -11% | -$10.9M |
|
|
10
Monte Rosa Therapeutics
GLUE
$1.4B
| $69.5M | 2.36% |
+3,193,973
| New | +$65.1M |
|
11
PUT
ARK Genomic Revolution ETF
ARKG
$1.57B
| $69.4M | 2.36% |
+750,000
| New | +$63.8M |
|
12
Edgewise Therapeutics
EWTX
$4.13B
| $66.5M | 2.26% |
3,140,914
+800,000
| +34% | +$21.9M |
|
13
PUT
ARK Innovation ETF
ARKK
$5.64B
| $65.4M | 2.22% |
+500,000
| New | +$58.3M |
|
|
RNAM
14
DELISTED
Avidity Biosciences
RNAM
| $55.1M | 1.87% |
2,228,667
-235,878
| -10% | -$5.49M |
|
|
APLS
15
DELISTED
Apellis Pharmaceuticals
APLS
| $53.7M | 1.82% |
850,000
-1,016,108
| -54% | -$52.4M |
|
16
ALX Oncology
ALXO
$261M
| $48.6M | 1.65% |
889,454
+7,684
| +0.9% | +$460K |
|
|
17
Biomea Fusion
BMEA
$84.6M
| $48.4M | 1.65% |
+3,170,872
| New | +$56M |
|
|
AMAM
18
DELISTED
Ambrx Biopharma Inc
AMAM
| $47M | 1.6% |
+2,486,386
| New | +$42.4M |
|
19
Zymeworks
ZYME
$1.61B
| $45.9M | 1.56% |
1,321,936
-678,064
| -34% | -$21.5M |
|
|
JBIO
20
Jade Biosciences
JBIO
$1.2B
| $44.6M | 1.52% |
+58,020
| New | +$46.4M |
|
|
RXDX
21
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $44.5M | 1.51% |
1,848,024
-250,000
| -12% | -$5.58M |
|
22
Tarsus Pharmaceuticals
TARS
$2.58B
| $43.9M | 1.49% |
1,514,269
-200,000
| -12% | -$6.25M |
|
23
Stoke Therapeutics
STOK
$1.8B
| $43M | 1.46% |
1,278,276
-159,531
| -11% | -$5.64M |
|
24
Rocket Pharmaceuticals
RCKT
$340M
| $42.9M | 1.46% |
968,550
-400,000
| -29% | -$17.4M |
|
|
VERV
25
DELISTED
Verve Therapeutics
VERV
| $40.6M | 1.38% |
+709,224
| New | +$29.4M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q2 2021 Portfolio in Review
As of Q2 2021, Cormorant Asset Management held 135 positions worth $2.94B, down 34% from $4.49B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Cormorant Asset Management withdrew a net $1.01B in Q2 2021, closing 31 positions and reducing 68 holdings. Its most notable exit was Novavax, an estimated $45.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 75% a quarter earlier, followed by Financials.
Against the trend, Cormorant Asset Management opened a new position in Monte Rosa Therapeutics worth $69.5M.
- Cormorant Asset Management's largest Q2 2021 buy was Monte Rosa Therapeutics: 3,193,973 shares worth $69.5M.
- Cormorant Asset Management added most to Revolution Medicines in Q2 2021, an estimated $28.4M increase.
- Cormorant Asset Management's biggest Q2 2021 reduction was C4 Therapeutics, cutting an estimated $76.5M.
- Cormorant Asset Management fully exited Novavax in Q2 2021, selling an estimated $45.3M.
- Cormorant Asset Management's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2021.
- Cormorant Asset Management opened 15 new positions and closed 31 in Q2 2021.
- Cormorant Asset Management's portfolio value fell 34% quarter-over-quarter to $2.94B.
Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.